Ventana Announces FDA Clearance for Progesterone Receptor (1E2) Image Analysis

Ventana Medical Systems, Inc., a member of the Roche Group, has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm Progesterone Receptor (PR) (1E2) image analysis application. The algorithm is for use with the VENTANA iScan Coreo Au scanner running VIRTUOSO software. This latest announcement comes shortly after Ventana received FDA clearances for the HER2 (4B5) and Ki-67 (30-9) image analysis and digital read applications.

The PR (1E2) image analysis algorithm assists pathologists in the detection and semi-quantitative measurement of PR expression in formalin-fixed, paraffin-embedded normal and neoplastic breast tissue. When used in conjunction with the VENTANA CONFIRM anti-PR (1E2) Rabbit Monoclonal Primary Antibody, it may be used to aid in the assessment of breast cancer patients for whom endocrine treatment is being considered but is not the sole basis for treatment.

The FDA clearance includes all of the components of the VENTANA laboratory workflow solution including the company’s BenchMark slide stainer, exclusive PR clone 1E2, detection systems, slide scanner, and image management software.

“The addition of the algorithm for PR (1E2) allows us to expand our Companion Algorithm image analysis offerings in the clinical market,” said Dr. Steve Burnell, Vice President, Ventana Digital Pathology and Workflow. “This newest addition to the VENTANA complete digital pathology workflow solution will assist pathologists in generating consistent and objective results. It is another example of our commitment to delivering the highest standards of patient care through the most advanced digital pathology solutions available.”

Ventana has also received FDA clearance for the digital read application that allows pathologists to interpret PR (1E2) stained slides as images on a computer monitor using the iScan Coreo Au scanner with VIRTUOSO software.